Product Description
FRTX-10 inhibits STING palmitoylation, thereby inhibiting the activation of STING and resulting in an efficient shutdown of the STING downstream pathway. Upon in vivo stimulation of mice with a STING agonist, oral administration of FRTX-10 was observed to reduce serum cytokine levels of IL-6 and IFN-b. (Sourced from: https://www.frtx.com/pipeline/frtx-10/)
Mechanisms of Action: STING Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Fresh Tracks Therapeutics
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Autoimmune Disease Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| None | P1 |
None |
Autoimmune Disease Unspecified |
None |
None |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
03/07/2023 |
News Article |
Fresh Tracks Therapeutics Announces Positive Topline Results from Single and Multiple Ascending Dose Parts of Phase 1 Study of Oral DYRK1A Inhibitor FRTX-02 |
|
09/07/2022 |
News Article |
Brickell Biotech Announces Corporate Rebranding to Fresh Tracks Therapeutics |